RFS.F Resverlogix Corp

Healthcare Biotechnology Frankfurt Exchange
0.0415 EUR
Close of Nov 13, 2026
0.0380 0.0860
Market cap
EUR 14.3M
P/E
-
P/B
46.41x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Apr 2026.

Is RFS.F undervalued?

Graham number

The Graham number of Resverlogix Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Resverlogix Corp fundamental analysis

No fundamental analysis for Resverlogix Corp yet.

Resverlogix Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Resverlogix Corp

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Service…

Full company profile